Literature DB >> 20353749

High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.

T-M-H Nguyen1, C Le Gall, A Lachaux, R Boulieu.   

Abstract

OBJECTIVE: Aminosalicylates are widely used with azathioprine in the treatment of IBD. The association results in an increase in 6-TGN levels in adults with IBD with a difference in the occurrence of myelotoxic effects. Scarce data are available in pediatric population. We proposed to investigate the effect of the coadministration of aminosalicylates on thiopurine concentrations in pediatric IBD patients.
MATERIALS AND METHODS: Data from 71 patients treated for at least 1 y by azathioprine and aminosalicylates were recorded. 6-TGN and 6-MeMPN concentrations, blood cell counts and liver function tests were compared between patients taking and those not taking aminosalicylates.
RESULTS: Aminosalicylate therapy was associated with a significant increase in mean 6-TGN but also 6-MeMPN concentrations. In patients in remission, 6-TGN level was related to aminosalicylate dosage (r = 0.561, p = 0.010). Lymphopenia rate was higher in patients receiving combined therapy compared to monotherapy whereas a slight rise in leucopenia was found.
CONCLUSIONS: This observation suggests that the higher frequency of lymphopenia may be associated with the elevated 6-TGN concentrations recovered in patients treated with aminosalicylates. This combination does not improve remission rate but could increase adverse effects especially lymphopenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353749     DOI: 10.5414/cpp48275

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

1.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

3.  Predictors of azathioprine toxicity in children with autoimmune hepatitis.

Authors:  Behairy El-Sayed Behairy; Hala Hany El-Said; Hatem Abd-Alsattar Konswa; Ahmed El-Sayed Nour El-Deen; Nermin Mohamed Adawy; Ahmad Mohamed Sira
Journal:  Clin Exp Hepatol       Date:  2021-03-25

4.  Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study.

Authors:  Berrie Meijer; Abraham J Wilhelm; Chris J J Mulder; Gerd Bouma; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  Ther Drug Monit       Date:  2017-08       Impact factor: 3.681

Review 5.  Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.

Authors:  Anastasia Konidari; Antonios Anagnostopoulos; Laura J Bonnett; Munir Pirmohamed; Wael El-Matary
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.

Authors:  Marius Vögelin; Luc Biedermann; Pascal Frei; Stephan R Vavricka; Sylvie Scharl; Jonas Zeitz; Michael C Sulz; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.